Wockhardt Limited

Brooks Labs IPO: Not worth investing

Brooks Laboratories has no reason for approaching the market. Capacity utilisation of one of its units has been stagnant at 68 percent for the last four years.

Wockhardt receives USFDA approval on heart-attack drug

Drug firm Wockhardt said it has received American health regulator's approval to market clopidogrel bisulfate tablets used for reducing risk of heart attack, in the US market.

Will China help Indian cos overcome FCCB woes?

Loans from Chinese banks could become an attractive funding source for some FCCB issuers.